References
- Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268–81.
- Magiorakos AP, Suetens C, Monnet DL, et al. The rise of carbapenem resistance in Europe: just the tip of the iceberg?. Antimicrob Resist Infect Control 2013;2:6.
- Freire-Moran L, Aronsson B, Manz C, et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now. Drug Resist Updat 2011;14:118–24.
- Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29–40.
- Whitfield C, Trent MS. Biosynthesis and export of bacterial lipopolysaccharides. Annu Rev Biochem 2014;83:99–128.
- Liu F, Ma S. Recent process in the inhibitors of UDP-3-O-(R-3-hydroxyacyl)-nacetylglucosamine deacetylase (LpxC) against Gram-negative bacteria. Mini Rev Med Chem 2018;18:310–23.
- Zhang J, Zhang L, Li X, Xu W. UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents. Curr Med Chem 2012;19:2038–50.
- Erwin AL. Antibacterial drug discovery targeting the lipopolysaccharide biosynthetic enzyme LpxC. Cold Spring Harb Perspect Med 2016;6:a025304.
- Coggins BE, Li X, McClerren AL, et al. Structure of the LpxC deacetylase with a bound substrate-analog inhibitor. Nat Struct Biol 2003;10:645–51.
- Clayton GM, Klein DJ, Rickert KW, et al. Structure of the bacterial deacetylase LpxC bound to the nucleotide reaction product reveals mechanisms of oxyanion stabilization and proton transfer. J Biol Chem 2013;288:34073–80.
- Onishi HR, Pelak BA, Gerckens LS, et al. Antibacterial agents that inhibit lipid A biosynthesis. Science 1996;274:980–2.
- Lee PS, Lapointe G, Madera AM, et al. Application of virtual screening to the identification of new LpxC inhibitor chemotypes, oxazolidinone and isoxazoline. J Med Chem 2018;61:9360–70.
- Hale MR, Hill P, Lahiri S, et al. Exploring the UDP pocket of LpxC through amino acid analogs. Bioorg Med Chem Lett 2013;23:2362–7.
- Mansoor UF, Vitharana D, Reddy PA, et al. Design and synthesis of potent Gram-negative specific LpxC inhibitors. Bioorg Med Chem Lett 2011;21:1155–61.
- Liang X, Lee CJ, Chen X, et al. Syntheses, structures and antibiotic activities of LpxC inhibitors based on the diacetylene scaffold. Bioorg Med Chem 2011;19:852–60.
- Lee CJ, Liang X, Chen X, et al. Species-specific and inhibitor-dependent conformations of LpxC: implications for antibiotic design. Chem Biol 2011;18:38–47.
- Liang X, Lee CJ, Zhao J, et al. Synthesis, structure, and antibiotic activity of aryl-substituted LpxC inhibitors. J Med Chem 2013;56:6954–66.
- Gao ZM, Wang TT, LI SZ, et al. Synthesis and antibacterial activity evaluation of (2-chloroquinolin-3-yl)methyleneamino guanidine derivatives. Chin J Org Chem 2016;36:2484–8.
- Yu HH, Zhou SC, Guo TT, et al. Synthesis and antimicrobial activity evaluation of aminoguanidine derivatives containing a biphenyl moiety. Chin J Org Chem 2019;39:1497–502
- Song MX, Wang SB, Wang ZT, et al. Synthesis, antimicrobial and cytotoxic activities, and molecular docking studies of N-arylsulfonylindoles containing an aminoguanidine, a semicarbazide, and a thiosemicarbazide moiety. Eur J Med Chem 2019;166:108–18.
- Sidoryk K, Świtalska M, Rózga P, et al. An efficient synthesis of indolo[2,3-b]quinoline guanidine derivatives with their in vitro and in vivo study. Med Chem Res 2017;26:3354–66.
- Wei ZY, Chi KQ, Yu ZK, et al. Synthesis and biological evaluation of chalcone derivatives containing aminoguanidine or acylhydrazone moieties. Bioorg Med Chem Lett 2016;26:5920–5.
- Osowska K, Lis T, Szafert S. Protection/deprotection-free syntheses and structural analysis of (*Keto-aryl)diynes. Eur J Org Chem 2008;27:4598–606.
- Qiu X, Janson CA, Smith WW, et al. Refined structures of β-ketoacyl-acyl carrier protein synthase III. J Mol Biol 2001;307:341–56.
- Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev 2009;22:582–610.
- Niu Y, Wang RE, Wu H, Cai J. Recent development of small antimicrobial peptidomimetics. Future Med Chem 2012;4:1853–62.
- Taubes G. The bacteria fight back. Science 2008;321:356–61.
- Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature 2000;406:775–81.
- Alekshun MN, Levy SB. Molecular mechanisms of antibacterial multidrug resistance. Cell 2007;128:1037–50.
- Makovitzki A, Avrahami D, Shai Y. Ultrashort antibacterial and antifungal lipopeptides. Proc Natl Acad Sci U S A 2006;103:15997–6002.
- Hoque J, Akkapeddi P, Yadav V, et al. Broad spectrum antibacterial and antifungal polymeric paint materials: synthesis, structure-activity relationship, and membrane-active mode of action. ACS Appl Mater Interfaces 2015;7:1804–15.
- Kosowska-Shick K, Clark C, Pankuch GA, et al. Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies. Antimicrob Agents Chemother 2009;53:4217–24.
- Heath RJ, Rock CO. Inhibition of beta-ketoacyl-acyl carrier protein synthase III (FabH) by acyl-acyl carrier protein in Escherichia coli. J Biol Chem 1996;271:10996–1000.
- Chu W-C, Bai P-Y, Yang Z-Q, et al. Synthesis and antibacterial evaluation of novel cationic chalcone derivatives possessing broad spectrum antibacterial activity. Eur J Med Chem 2018;143:905–21.
- Zhang HJ, Qin X, Liu K, et al. Synthesis, antibacterial activities and molecular docking studies of Schiff bases derived from N-(2/4-benzaldehyde-amino) phenyl-N′-phenyl-thiourea. Bioorg Med Chem 2011;19:5708–15.